Thrombocytopenia and thrombosis in hospitalized patients with COVID-19
- PDF / 655,075 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 14 Downloads / 181 Views
Open Access
EDITORIAL
Thrombocytopenia and thrombosis in hospitalized patients with COVID‑19 Heng Mei1,2, Lili Luo1,2 and Yu Hu1,2*
Abstract As our understanding on coronavirus disease 2019 (COVID-19) deepens, it is increasingly recognized that COVID-19 is more than a respiratory condition. Thrombocytopenia and thromboembolic complications are a composite factor associated with critical COVID-19 and increased mortality. Immune-inflammation-mediated destruction, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection per se and increased consumption are proposed to be responsible for thrombocytopenia. Multiple concomitant conditions or results caused by SARS-CoV-2 infection are high risk factors for thrombosis. Recently, platelet activation and platelet-mediated immune inflammation induced by SARS-CoV-2 infection were also found to be the contributors to the thrombosis in COVID-19 patients. In addition to thrombus scoring system, D-dimer is an excellent indicator for monitoring thrombosis. COVID-19 patients with high risk for thrombosis should be subjected to early thromboprophylaxis, and prolonged activated partial-thromboplastin time should not be a barrier to the use of anticoagulation therapies in the control of thrombosis in COVID-19 patients. Keywords: COVID-19, Thrombocytopenia, Thrombosis Starting in December 2019, coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a public health crisis around the world. As the seventh known human coronavirus genus, SARS-CoV-2 is comparable to SARS-CoV and Middle East respiratory syndrome coronavirus in that they all cause unusual viral pneumonia. As we gain further insights into the condition, COVID-19 is more a systemic condition than it is a respiratory disease, especially in severe cases. Mounting evidence has revealed that thrombocytopenia and thromboembolic complications are associated with disease severity and increased mortality [1, 2].
*Correspondence: [email protected] 1 Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China Full list of author information is available at the end of the article
Phenomenon and mechanisms of thrombocytopenia in COVID‑19 A national multicentre retrospective study conducted in China revealed that the incidence of thrombocytopenia (
Data Loading...
